|
Medications:
One of the disadvantages that is not truly a disadvantage but a theoretical disadvantage is that physicians have been
using methotrexate now probably for over 20 years in rheumatoid arthritis, and easily in many of the patients,for the last
dozen years in rheumatoid arthritis. So, there is a long track record with methotrexate, and physicians know many of its side
effects including liver and bone marrow troubles.
They have a long track record with methotrexate, and they know many of its side effects including liver and bone marrow
troubles.
With biologics we don't have this large, robust group of patients who've been on it for ten years. As a matter of fact,
we don't have that at all. However, researcher-investigators just presented the five-year data on Enbrel at an arthritis meeting
showing that Enbrel over a five-year period of time was safe. They've published in The Journal of Rheumatology the four-year
data, again showing that Enbrel as a biologic was a safe therapy in patients with rheumatoid arthritis. So, again, a
theoretical disadvantage would be,not knowing what the ten-year data shows, as of to day.
Remicade has some other concerns that Enbrel doesn't. Since it's called a chimeric protein -- chimeric definition means
it's made of two animals, or one is mouse, and one is human -- one has this allergic problem and one does have to take it
with something else such as methotrexate, although recently scientists presented data showing safety in taking Remicade or
infliximab with a newer drug called leflunomide or Arava. One takes this intravenously so that you go to the doctor every
two months, and that may be an advantage to the patient, but one could have more allergic problems with the Remicade with
the Enbrel.
Arava or leflunomide came on the scene about the same time, actually, or just before Enbrel, about 1998. I've been
working with this compound since the mid-'90s and actually some patients are on it over five years now, and it can be used
as what's called monotherapy, meaning as a single agent, much as physicians would use Enbrel as a single agent or they would
use methotrexate as a single agent.
Remicade needs to be used in combination with something else. Arava has been shown to be able to be mixed with,Remicade
in clinical trials, and it's been able to be mixed with methotrexate in a study from the Albany Medical Center showing again
that again careful monitoring, that one could mix these compounds, and it adds a choice to patients with rheumatoid arthritis.
It would be wonderful if a drug was available that worked for everyone. Then they wouldn't need rheumatologists. They
could just go to the local pharmacy and say that they want the treatment for rheumatoid arthritis. Methotrexate
is the gold standard of DMARDs,but unfortunately it doesn't work for everyone. Scientists doing their clinical research and
clinical trials and evidence-based medicine, they often do placebo-controlled trials, meaning the patients and the doctors
don't know if they're getting methotrexate or if they're getting placebo. They also do comparative studies such as comparing
head to head, which they've done in clinical trials and have published -- methotrexate versus Arava, methotrexate versus Enbrel.
And if you look at the data, methotrexate again, in a research unit where the patients are carefully followed and the
patients are blinded and don't know if they're getting methotrexate or not and the physician doesn't know, really is about
a 50 to 60 percent good medicine. We're looking at about 40 percent of patients who really don't respond to methotrexate.
And that's why the 1990s were the age when rheumatologists before they had biologics were mixing many medicines with methotrexate,
and physicians still do mix many medicines with methotrexate, and that's because patients have incomplete responses or don't
have responses to methotrexate.
If we look at the clinical information, and one has to do this with a special caveat because none of these groups of
rheumatoid patients are exactly equal, but if we look at the group of patients on Remicade, we're getting responses in the
same ballpark as we did with methotrexate alone although those probably were more difficult patients. Not that the patients
were difficult, but their arthritis was.
If we look at the Enbrel data, on the other hand, we're getting responses that are better, and if we look at our long-term
studies over the long haul, it looks like that Enbrel is probably a little bit better and more likely to work than methotrexate.
Biologics are currently costly and health administrators (payers) feel methotrexate will do the "job".
This protein called TNF is increased in rheumatoid arthritis in the joint as well as in the joint fluid of patients with
rheumatoid arthritis. This protein is called a cytokine. A hormone is -- much like thyroid hormone is a protein that's made
in the thyroid gland in the neck and then is shipped around the body to tell the rest of the body what to do. Normal
people have TNF in their bodies,but it is kept in balance. People with RA have an excess of tumour necrosis factor (TNF).
A cytokine is a hormone. It's a protein shipped around the body to tell the body what to do, but it can be made not just
in one place like thyroid but it could be made in many different cells and many different places in the body. One should think
of the cytokine, as the communication centre in immune system. It says "Foward March-," and it goes to all of your joints
and causes arthritis and goes to the rest of the system and causes things such as fatigue,pain etc.
The other cytokine besides TNF that is increased in rheumatoid arthritis is a cytokine that's called called IL-1, and
IL-1, much like TNF, has a naturally occurring blocker that's in balance like TNF,has a natural soluble TNF receptor, which
Enbrel is, that puts us back in balance in the body. The anakinra or Kineret, the new biologic, is a balancer of this increased
cytokine that causes arthritis, and it's an interleukin-1 cytokine balancer.
Many physicians now,have gotten very comfortable using methotrexate, and therefore methotrexate is often the first therapy
started just because of comfort levels.
Biologics, or especially the anti-TNF agents, are becoming actually traditional choices in rheumatoid arthritis, and
Kineret will probably be used in patients who are not doing quite as well either on one of the older biologic agents such
as Enbrel or Remicade or patients who are not quite doing as well, let's say, on methotrexate or Arava.
"Kineret will probably be used in patients who are not doing quite as well either on one of the older biologic
agents such as Enbrel or Remicade."
Investigator-scientists actually did a study and presented this at the last national arthritis meeting where they combined
anakinra or Kineret with Enbrel, and there was a slight increased risk of infection. Right now,they're studying that to see
if that's dose-related or how they can adjust the doses to make this work,currently, that is not a standard recommendation,
but mixing Kineret with methotrexate or with Arava has been shown to be safe and efficacious.
Huminra (under clinical trials-DE27) is a totally humanized TNF inhibitor,recently approved for the treatment of RA by
the FDA.
Enbrel, which is etanercept, and infliximab, the trade name is Remicade. They both are targeted towards the inflammatory
messenger called TNF or tumor necrosis factor, and these are similar in many ways. Enbrel is actually the receptor that TNF
binds to on the inflammatory cell, and this brilliant biotechnology company figured out how to make that little receptor and
how to help it circulate in the blood, and so what it acts as a sponge to take this out of circulation. The infliximab or
Remicade is a little different in that instead of just a receptor floating around, infliximab is an antibody, and that is
it binds specifically to TNF and in the same way sponges it out of the blood.
Enbrel is really a nice drug because individuals can administer that to themselves, and so that gives them a measure
of control and independence. It's also not really associated with a meaningful immune response, so it can be taken all by
itself.
Remicade is also a terrific treatment, but it is a little different in that it needs to be given as an intravenous
treatment, and because one third of Remicade comes from a mouse, they have to take a drug like methotrexate with it to suppress
making anti-mouse antibodies
Enbrel, which is etanercept, and infliximab, the trade name is Remicade. They both are targeted towards the inflammatory
messenger called TNF or tumor necrosis factor, and these are similar in many ways. Enbrel is actually the receptor that TNF
binds to on the inflammatory cell, and this brilliant biotechnology company figured out how to make that little receptor and
how to help it circulate in the blood, and so what it acts as a sponge to take this out of circulation. The infliximab or
Remicade is a little different in that instead of just a receptor floating around, infliximab is an antibody, and that is
it binds specifically to TNF and in the same way sponges it out of the blood.
If patients fail on an initial agent such as methotrexate need to be considered for a biologic, if it is infliximab or
Remicade, because of the mouse protein in it, one has to continue the methotrexate whereas with Enbrel or etanercept, it can
be used as a single agent with very good success.
The most important message is to treat early and to treat aggressively and to do whatever it takes to suppress an individual's
inflammatory arthritis, and , using a potent disease-modifying drug like methotrexate immediately is often the correct answer,
but if they don't have substantial suppression of their disease that moving along and adding biological therapy be very rapidly
considered, even perhaps in individuals with very aggressive disease in the first three to four months of therapy.
The other important point for the patient is,if they or some of their loved ones may have rheumatoid arthritis is that
not all of these medicines work for every patient, and physicians have to make decisions which are go, no-go decisions whether
this is the right medicine and the right dose of medicine for the patient. Being on one of these medications is not enough.
The rheumatologist and the physician taking care of the patient has to make a decision whether it's really doing
the job that it needs to be done. Therefore, physicians will look at the patient's joints and they'll actually
do a joint count (not always )so they can find out how many of the joints are tender and how many are swollen, and most
physicians will follow x-rays on a periodic basis to be sure that there is no damage that's progressing to make decisions
whether or not this is an effective medicine, whether it be a biologic such as Enbrel or a synthetic such as methotrexate.
Why not start on the biologics immediately for most of the patients? --One could really make a case for that.-- One of
the things that we as a society have to come to grips with is that the cost of biologics is much more than methotrexate is.
And , while there are individuals that without any question should be started on the biologics first, like people with significant
liver disease or someone who has moderately severe kidney disease, in most individuals who do not have those processes, probably
an initial trial of a potent disease-modifying pharmaceutical like methotrexate is probably from a financial standpoint the
most sensible thing, and probably from a societal standpoint
Also, many of the patients with rheumatoid arthritis often come already on methotrexate. Many internal medicine doctors
have already started them on methotrexate, and a decision needs to be made is that the right medicine and if so, is it the
right dose, and often it's too low, and one pushes the dose. A comparative study has been shown that higher doses of methotrexate
work better. This is a very individual decision with the patient and the physician.
What physicians focus the most on isn't necessary what is the first drug that is used but that these biologics are not
something that should be saved until there are no other options. These are drugs that should be used easily in the first six
months to a year of disease if traditional therapies don't very effectively suppress the arthritis.
People should not wait because, the pace and the progression of joint damage is a continuous and rapid process, and if
we can in a rapid fashion suppress people's disease, that over many years will reduce the amount of joint damage which should
translate into better work, better health, and better social function.
The good news for our patients with rheumatoid arthritis is that we are in a new era of therapeutic intervention. Physicians,25,
27 years ago, were making patients some better. Now,rheumatologists and the rheumatoid arthritis patient are asking and doctor's
are trying to return them to normal lives, and they're trying to slow if not stop the progression of their disease.
Hopefully, we're going to do see this, and hopefully,going to do this with less side effects, especially with some of
these targeted biologics.
Note: Physicians are being advised to "use caution" when prescribing Wyeth and Amgen's arthritis drug Enbrel (etanercept)
in patients with congestive heart failure (CHF) because of the possibility that the therapy may worsen their condition.
An updated European summary of product characteristics says: "There have been postmarketing reports of worsening of CHF,
with and without identifiable precipitating factors, in patients taking Enbrel."
"Two large clinical trials evaluating the use of Enbrel in the treatment of CHF were terminated early due to lack of
efficacy. Although not conclusive, data from one of these trials suggest a possible tendency toward worsening CHF in those
patients assigned to Enbrel treatment."
The drug label's special warnings section says allergic reactions have been reported commonly.(other warnings are listed
on label)
"In postmarketing experience, allergic reactions have included angioedema and urticaria as well as serious reactions.
If any serious allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and appropriate
therapy initiated."
It also notes that sepsis and serious infections have been reported and advises that "administration of Enbrel should
be discontinued if a patient develops a serious infection.
Individual patient factors account for a substantial proportion of the between-patient differences in response to disease-modifying
antirheumatic drugs (DMARDs), according to a report in the January issue of the Annals of the Rheumatic Diseases.
About a quarter of patients with rheumatoid arthritis (RA) fail to respond to DMARDs from the outset of treatment, the
authors explain, and another quarter may stop responding after an initial period of efficacy. The reasons for these differences
are unclear.
Ms. Cathy Morgan from the University of Manchester Medical School in the UK and colleagues studied 265 patients with RA
to identify those with resistance to at least one DMARD and to determine what portion of the variance in drug response arose
from patient-related factors.
Forty percent of patients experienced failure of at least one DMARD due to inefficacy, the authors report, and 11% experienced
failure of at least 2 DMARDs. Only 5% of patients had multidrug resistance (unresponsiveness to at least 3 DMARDs).
The 13 patients in the multidrug-resistant group were significantly younger than patients who had responded to DMARDs,
the report indicates, and all were women.
In a random effects model, 35% of the variance of the probability of DMARD failure derived from differences between patients,
while the remaining 65% arose from differences between drugs or from chance alone.
Rheumatoid factor status accounted for 3% of this variance (with a positive result increasing the likelihood of treatment
failure), the results indicate, but the remainder of the between-subject variance remained significant.
Among the patient-related factors mentioned by the investigators that may contribute to DMARD failure were patient non-adherence
to treatment, undiagnosed malabsorption states, and the irrelevance of particular drugs to the responsible disease mechanisms
in some RA subgroups. This study was not, however, designed to identify such variables.
"Further understanding of the variance in drug response between subjects may suggest new therapeutic strategies and targets
in RA," Morgan and colleagues write
Ann Rheum Dis 2003;62:15-19.
Analgesics are medications that relieve pain without reducing imflammation. Analgesics are highly effective at reducing
mild or moderate pain similar to that of a headache or toothache. They do do not have the side effects have the side effects
common in other medications such as NSAIDs.
Analgesics work quickly,usually within an hour. The relief from pain generally lasts from 4 to 8 hours. These medications
work by preventing pain signals from being sent in the first place or by preventing your brain from receiving and interpreting
pain impulses.
Acetaminophen,one of the most commonly used analgesic is the active ingrediant in a number of over-the-counter medications
including brand names such as Anacin, Excedrin, and Tylenol.
Sometimes acetaminophen is combined with other substances such as caffeine, which might make you jittery and keep you
up at night,or antihistamines,which might make you drowsy. Acetaminophen at high doses is not recommended,in fact it can be
damaging to the liver.
Topical analgesics provide pain relief locally-at a particular joint or joints-rather then systemically. This type of
medication is available in creams, lotions, or gels that are spread on the surface of the skin and then penetrate within.
If you have mild arthritis pain that is limited to one or two joints or if you want to supplement the effectiveness of an
oral medication,topical analgesics may be a good option.
A variety of topical analgesics are available in drugstores. Most work in one of three ways. Some distract the nerves
with another type of irritant. Known as counter irritants,these contain ingrediants such as menthol, eucalyptus oil,or turpentine
oil. Typical brand names are ArthriCare,Icy Hot,and Mineral Ice. How effective they are are uncerain.
Some topical analgesics relieve pain tenporarily by delivering salicylates ( aspirin ingrediant ) through the skin. The
topical form appears to inhibit the chemical prostaglandins just as the oral form does and also dis tracts the nerves through
counterirritants. Brand names include Ben-Gay,Mobisyl and Sporscreme. The effectiveness of these is still being debated.
The third type of topical analgesic works by counter ing a chemical substance in the body called substance P,a neurotransmitter
that appears to transmit nerve signals to the brain. These creams contain a derivative of a natural ingrediant found in cayenne
(hot) pepper. As such,they may burn or sting when first used. They are marketed under the names such as Capzasin-P and Zostrix.
Topical analgesics are not recommended for use on broken or irritated skin. They also should not be used with a heating
pad because it may result in a burn. After applying the cream,be sure to wash your hands before touching your eyes.
At low doses NSAIDs relieve pain;at higher doses they also reduce inflammation Such non-selective NSAIDs include aspiring,ibuprofen
(brand names include Advil and Motrin )and naproxen. Aspirin has many risks therefore it is not recommended for the treatment
of arthritis. The Cox-2 was so highly publisized when it first appeared,they were the saviour,but in medicine it is not that
simple. Those medications also have risks involved-some are dose related and some on the condition or age of the patient.
Although all NSAIDs share a common mechanism of pain relief.they vary in the amount of time that they remain active or
half-life. Short acting NSAIDs with half-lives ranging from one to eight hours include ibuprofen (Advil, Motrin),ketoprofen
( Actron,Orundis ),and Flurbiprofen ( NSAID) These are taken more often per day.
NSAIDs with a longer half-life ( ranging from 12 to 24 hours and sometimes longer ) include naproxen,piroxicam ( Feldene
) and nabumetone ( Relafen which is supposed to be also easier on the stomach ) These longer-acting agents provide pain relief
over an extended period and may be taken less often.
Another important point is that two NSAIds made be similar,but patient reactions to one medication may be different from
another. Put simply,if one NSAID does not appear to work,try another. You must work with your doctor to find one which is
appropriate for you.
No medication is risk free. NSAIDs in some patients may cause more problems then DMARDs,especially with some one who
has another underlying disease present or with elder patients. The risk of NSAID side effects generally appear to be directly
related to the dose and the amount of time one takes it. Sometimes we also grow more sensitive to the effect of a given drug
as we age,possibly because of differences in how we metabolize drugs or because we are taking other medications.
When side effects are experienced or when the NSAID seems to be not working for you,consult your physician who in turn
may switch medications.
Ironically,it is the very ability to block a pain signal that gives a NSAID such power not only to help,but hurt. At
the centre of this paradox is the enzyme, COX (cyclooxygenase). This enzyme then helps produce chemicals called prostaglandins,
around the site of inflammation. By inhibiting production of COX,NSAIDs prevent this from happening Cox-1 produces prostaglandins
that help maintain the lining of the stomach.
Cox-2 also produces prostaglandins, but these are primarily involved in sending pain signals and encouraging the process
of inflammation. Because traditional NSAIDS block both types of Cox enzymes,they relieve pain but may also adversely affect
the stomach and kidneys. In fact,the most frequent cited side effects of NSAIDs is mild stomach upset ( which affect 30 to
40 % of those taking it ).
But NSAIDs use can also lead to more serious problems. These include the develoment of stomach problems which can hemmorage
and perforate. Researchers have identified others at risk for such complications those with a history of ulcers,advanced disability,taking
higher dosage of NSAIDs and corticosteriods at the same time,and older age groups.
NSAIDs can cause a whole host of problems in some people (with underlying other disease ) but in the majority,it can
be found,if detected,before more serious problems arise. Many people do not get serious side effects.
COX is not one enzyme,as scientists once believed,but two (and new research suggests there could be several versions
). Cox-1 produces prostaglandins that help maintain the lining of the stomach. Cox-2 also produces prostaglandins, but these
are primarily involved in sending pain signals and encourageing the inflammatory process.
An overdose of acetaminophen can cause liver damage. This damage occurs in a dose-related manner. (Some other medications
can cause liver injury in an unpredictable fashion that is unrelated to the dose.) In other words, liver injury from acetaminophen
occurs only when someone takes more than a certain amount of the drug.
Likewise, the higher the dose, the greater is the likelihood of the damage. What is more, this liver injury from an overdose
of acetaminophen is a serious matter because the damage can be severe and result in liver failure and death. In fact, acetaminophen
overdose is the leading cause of acute (rapid onset) liver failure in the U.S. and the United Kingdom.
For the average healthy adult, the recommended maximum dose of (Tylenol )acetaminophen over a 24 hour period is
four grams (4000 mg) or eight extra-strength pills. (Each extra-strength pill contains 500 mg and each regular strength pill
contains 325 mg.) A person who drinks more than two alcoholic beverages per day, however, should not take more than two grams
of acetaminophen over 24 hours, as discussed below.
For children, the dose is based on their weight and age, and explicit instructions are given in the package insert. If
these guidelines for adults and children are followed, acetaminophen is safe and carries essentially no risk of liver injury.
On the other hand, a single dose of 7 to 10 grams of acetaminophen (14 to 20 extra-strength tablets) can cause liver
injury in the average healthy adult. Note that this amount is about twice the recommended maximum dose for a 24 hour period.
In children, a single dose of 140 mg/kg (body weight) of acetaminophen can result in liver injury. Amounts of acetaminophen,
however, as low as 3 to 4 grams in a single dose or 4 to 6 grams over 24 hours have been reported to cause severe liver injury
in some people, sometimes even resulting in death.
It seems that certain individuals, for example, those who regularly drink alcohol, are more prone than others to developing
acetaminophen-induced liver damage. To understand this increased susceptibility in some people, it is useful to know how acetaminophen
is processed (metabolized) in the liver and how the drug causes liver injury.
How is acetaminophen processed (metabolized) in the body? The liver is the primary site in the body where acetaminophen
is metabolized. In the liver, acetaminophen first undergoes sulphation (binding to a sulphate molecule) and glucuronidation
(binding to a glucuronide molecule) before being eliminated from the body by the liver. The parent compound, acetaminophen,
and its sulphate and glucuronide compounds (metabolites) are themselves actually not harmful.
An excessive amount of acetaminophen in the liver, however, can overwhelm (saturate) the sulphation and glucuronidation
pathways. When this happens, the acetaminophen is processed through another pathway, the cytochrome P-450 system. From acetaminophen,
the P-450 system forms an intermediate metabolite referred to as NAPQI, which turns out to be a toxic compound. Ordinarily,
however, this toxic metabolite is rendered harmless (detoxified) by another pathway, the glutathione system.
There's a menu of many laboratory tests involved in inflammatory arthritis,an inevitable consequence of employing
most DMARD therapy,beginning with a blood sample. The rheumatologist will use the information from several test categories
to help diagnose our condition,check for side effects,and monitor response for treatment.
Usually,there are 5 to 7 tests per DMARD,but all can be done from one blood sample;if the DMARD is switched,another sample
will be taken,since each medication is tested for different specifics.
Some DMARDs can lower the production of white blood cells,which are critical to the body's defence against infection
and other health concerns. Others can affect how the liver or kidneys work. Lab tests can detect such changes long before
symptoms are experienced,giving the physician a chance to adjust dose or switch DMARDs.
Without that critical information.DMARD therapy is definitely riskier. Whether it's weekly ( for blood and urine tests,as
with gold injections ) or 6 -8 weeks (blood tests for methotrexate,sulfasalazine;and azathioprine ) or semi-annual or annual
eye examinations ( hydroxochloroquine ) keep your lab appointments faitfully.
If a severe or persistent infection develops ( lasting longer than a week ),some DMARDs,such as methotrexate and azathioprine,may
be stopped until it clears up or switched. If you are going to a family doctor,make sure your rheumatologist knows,so steps
can be taken to prevent a flare-up,which can occur as the amount of medication in your body decreases.
Ask the rheumatologist to explain what the different tests are for and how they're interpreted. Being in the know will
reduce anxiety about those mysterious results and help put adjustments to the medication regimen into perspective. That may
help make it easier when the going gets tough,and staying on course can make a big difference in our health
|